Dana-Farber Cancer Institute authors: Giuseppe Tarantino, PhD, David Liu, MD, MPH ...

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...

Spanish scientists working in Austria have observed in mice that some medicines can thwart the trick tumors use to evade ...

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for ...

Studying patients with PD-1 or PD-L1 deficiency may help inform new approaches to fine-tuning immunotherapies to maximise ...

AI-081 is a differentiated bispecific antibody with robust cooperative interactions between PD1 and VEGFDosing of first patient in BIPAVE-001 ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies ...

Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally ...

Findings indicate a serine/glycine-free diet can reduce colorectal cancer growth and enhance immune response, offering ...

Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on REPL stock, giving a Buy rating on November 22.Don't Miss our ...